Abstract
Passive immunotherapy with plasma-derived immunoglobulins has been used successfully for the treatment of immunodeficiency diseases since the 1950s. Intravenous immune serum globulin (IVIG), available since the early 1980s, is a safe and effective therapy in patients with humoral immune or antibody deficiencies. The rationale for the use of IVIG is the prevention of acute and chronic infections. This article discusses the use of IVIG for patients with immunodeficiency disorders. Detail of dosages, various routes of administration, metabolism, products available in the United States, and possible adverse effects of IVIG are discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 165-184 |
| Number of pages | 20 |
| Journal | Immunology and Allergy Clinics of North America |
| Volume | 21 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2001 |
Fingerprint
Dive into the research topics of 'Replacement intravenous immune serum globulin therapy in patients with antibody immune deficiency'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver